Thomas K. Hansen

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Christopher Sorli, Shin‐ichi Harashima, George Tsoukas et al. · The Lancet Diabetes & Endocrinology · 2017 · 707 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Lawrence A. Leiter, Stephen C. Bain, Irene Hramiak et al. · Cardiovascular Diabetology · 2019 · 162 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials

Johannes F.E. Mann, Thomas K. Hansen, Thomas Idorn et al. · The Lancet Diabetes & Endocrinology · 2020 · 149 citations

Medicine, Nephrology, Pharmacotherapy +17

Discovery and SAR of a Novel Selective and Orally Bioavailable Nonpeptide Classical Competitive Inhibitor Class of Protein-Tyrosine Phosphatase 1B

Henrik Sune Andersen, Ole H. Olsen, Lars Iversen et al. · Journal of Medicinal Chemistry · 2002 · 133 citations · Full text

Life Sciences, Biochemistry, Pharmacology +14

Crown ether derivatives of tetrathiafulvalene. 1

Thomas K. Hansen, T. Joergensen, Paul C. Stein et al. · The Journal of Organic Chemistry · 1992 · 131 citations

Natural Sciences, Chemistry, Analytical Chemistry +4